Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

radioligand therapy

  • Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    You have access
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    Vishnu Murthy, Andrei Gafita, Pan Thin, Kathleen Nguyen, Tristan Grogan, John Shen, Alexandra Drakaki, Matthew Rettig, Johannes Czernin and Jeremie Calais
    Journal of Nuclear Medicine September 7, 2023, jnumed.122.265155; DOI: https://doi.org/10.2967/jnumed.122.265155
  • Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
    Open Access
    Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
    Yizhen Pang, Liang Zhao, Jianyang Fang, Jianhao Chen, Lingxin Meng, Long Sun, Hua Wu, Zhide Guo, Qin Lin and Haojun Chen
    Journal of Nuclear Medicine September 1, 2023, 64 (9) 1449-1455; DOI: https://doi.org/10.2967/jnumed.123.265599
  • [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
    You have access
    [177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
    Lorenzo Mercolli, Clemens Mingels, Giulia Manzini, Paul Cumming, Konstantinos Zeimpekis, Song Xue, Ian Alberts, Dominik Uehlinger, Axel Rominger, Kuangyu Shi and Ali Afshar-Oromieh
    Journal of Nuclear Medicine August 24, 2023, jnumed.123.265577; DOI: https://doi.org/10.2967/jnumed.123.265577
  • Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&amp;T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
    You have access
    Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
    Robert Tauber, Karina Knorr, Margitta Retz, Isabel Rauscher, Sonia Grigorascu, Kimberley Hansen, Calogero D’Alessandria, Hans-Jürgen Wester, Jürgen Gschwend, Wolfgang Weber, Matthias Eiber and Thomas Langbein
    Journal of Nuclear Medicine August 1, 2023, 64 (8) 1244-1251; DOI: https://doi.org/10.2967/jnumed.122.265259
  • [<sup>177</sup>Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis
    You have access
    [177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis
    Swayamjeet Satapathy, Ranjit K. Sahoo and Chandrasekhar Bal
    Journal of Nuclear Medicine August 1, 2023, 64 (8) 1266-1271; DOI: https://doi.org/10.2967/jnumed.123.265414
  • Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy
    You have access
    Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy
    Philipp E. Hartrampf, Patrick W. Mihatsch, Anna Katharina Seitz, Lilja B. Solnes, Steven P. Rowe, Martin G. Pomper, Hubert Kübler, Thorsten A. Bley, Andreas K. Buck and Rudolf A. Werner
    Journal of Nuclear Medicine August 1, 2023, 64 (8) 1272-1278; DOI: https://doi.org/10.2967/jnumed.122.265379
  • Albumin-Binding and Conventional PSMA Ligands in Combination with <sup>161</sup>Tb: Biodistribution, Dosimetry, and Preclinical Therapy
    You have access
    Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
    Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli and Cristina Müller
    Journal of Nuclear Medicine July 13, 2023, jnumed.123.265524; DOI: https://doi.org/10.2967/jnumed.123.265524
  • PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study
    You have access
    PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study
    Masatoshi Hotta, Andrei Gafita, Vishnu Murthy, Matthias R. Benz, Ida Sonni, Irene A. Burger, Matthias Eiber, Louise Emmett, Andrea Farolfi, Wolfgang P. Fendler, Manuel M. Weber, Michael S. Hofman, Thomas A. Hope, Clemens Kratochwil, Johannes Czernin and Jeremie Calais
    Journal of Nuclear Medicine July 1, 2023, 64 (7) 1024-1029; DOI: https://doi.org/10.2967/jnumed.122.265242
  • Fibroblast Activation Protein–Targeted Radioligand Therapy for Treatment of Solid Tumors
    You have access
    Fibroblast Activation Protein–Targeted Radioligand Therapy for Treatment of Solid Tumors
    Spencer D. Lindeman, Ramesh Mukkamala, Autumn Horner, Pooja Tudi, Owen C. Booth, Roxanne Huff, Joshua Hinsey, Anders Hovstadius, Peter Martone, Fenghua Zhang, Madduri Srinivasarao, Abigail Cox and Philip S. Low
    Journal of Nuclear Medicine May 1, 2023, 64 (5) 759-766; DOI: https://doi.org/10.2967/jnumed.122.264494
  • Prognostic Value of Tumor Volume Assessment on PSMA PET After <sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
    You have access
    Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
    Felix Kind, Ann-Christin Eder, Cordula A. Jilg, Philipp E. Hartrampf, Philipp T. Meyer, Juri Ruf and Kerstin Michalski
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 605-610; DOI: https://doi.org/10.2967/jnumed.122.264489

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire